We’ll primarily focus on the dose-expansion part. The phase 2 trial was focused on ROS1- positive NSCLC. There were also other cohorts for patients with nonlung cancer with ROS1 fusion. ROS1 can ...

Welcome to the NavRL repository! This repository provides the implementation of the NavRL framework, designed to enable robots to safely navigate dynamic environments using Reinforcement Learning.

Panelists discuss next-generation ROS1 inhibition, highlighting emerging therapies, their mechanisms of action, and potential benefits for patients with ROS1-positive metastatic non–small cell lung ...

In this repository is the code to explore ARID1A-driven resistance mechanisms in melanoma treated with BRAF and MAPK inhibitors. This repository contains the code integrating transcriptomics, ...